Does Bromelain-Cisplatin Combination Afford In-Vitro Synergistic Anticancer Effects on Human Prostatic Carcinoma Cell Line, PC3?
Galen Med J. 2020 ;9:e1749. Epub 2020 Aug 29. PMID: 34466585
Fatemeh Amini Chermahini
Background: Bromelain enhances anticancer impacts to chemotherapeutic agents. The question as to whether bromelain does promotecytotoxic and proapoptotic effects of cisplatin on human prostatic carcinoma PC3 cell line was investigated.
Materials and Methods: PC3 (human prostatic carcinoma) cells were treated either single or in combination with bromelain and/or cisplatin. MTT, clonogenic assay, flow cytometry and real-time quantitative polymerase chain reaction were used to investigate cell viability, colony formation, proapoptotic potential andgene expression, respectively.
Results: Cisplatin (IC) combined with bromelain (IC) significantly affected PC3 cell viability, inhibited colony formation, as well increasedproapoptotic gene expression compared to cisplatin single treatment. Nevertheless, bromelain-cisplatin chemoherbal combination did not display any additive proapoptotic effect compared to single treatments.
Conclusion: Bromelain-cisplatin chemoherbal combination demonstrated synergisticanticancer effect on human prostatic carcinoma cell line, PC3, that drastically reduced required cisplatin dose.